New antidote for blood thinner shows promise in early trial

NCT ID NCT03172910

Completed Disease control Sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 2 study tested a drug called ciraparantag in 69 healthy adults aged 50 to 75 who were given the blood thinner rivaroxaban. The goal was to see if ciraparantag could quickly reverse rivaroxaban's effects and restore normal clotting. Participants received either ciraparantag or a placebo, and their clotting time was measured over several hours. The study is complete, and results will help determine if ciraparantag could be used as an antidote for bleeding emergencies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ciraparantag (also called PER977 or AMAG 977)
What this could lead to: If successful, ciraparantag could become a fast-acting antidote to reverse the effects of rivaroxaban, helping stop or prevent dangerous bleeding.
What could go wrong: This is an early Phase 2 study in only 69 healthy volunteers, not patients with bleeding. The reversal effect may not work as well in real-world emergencies, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Show contact details

Locations

Frontage Clinical Services Inc.

Secaucus, New Jersey, 07094, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.